Skip to content
The Policy VaultThe Policy Vault

Afinitor Disperz — CareFirst (Caremark)

neuroendocrine tumors of the pancreas

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months